• 1
    Van Riel PL, Wijnands MJ, van de Putte LB. Evaluation and management of active inflammatory disease. In: KlippelJH, DieppePA, editors. Rheumatology. 2nd ed. London: Mosby; 1998. p. 5.14.113.
  • 2
    Williams DG. Autoantibodies in rheumatoid arthritis. In: KlippelJH, DieppePA, editors. Rheumatology. 2nd ed. London: Mosby; 1998. p. 5.9.18.
  • 3
    Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 13839.
  • 4
    Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002; 41: 80914.
  • 5
    Jikimoto T, Nishikubo Y, Koshiba M, Kanagawa S, Morinobu S, Morinobu A, et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 2002; 38: 76572.
  • 6
    Masuda M, Morimoto T, de Haas M, Nishimura N, Nakamoto K, Okuda K, et al. Increase of soluble FcgRIIIa derived from natural killer cells and macrophages in plasma from patients with rheumatoid arthritis. J Rheumatol 2003; 30: 19117.
  • 7
    Pinheiro GR, Andrade CA, Gayer CR, Coelho MS, Freire SM, Scheinberg MA. Serum vascular endothelial growth factor in late rheumatoid arthritis. Clin Exp Rheumatol 2001; 19: 7213.
  • 8
    Tchetverikov I, Lard LR, deGroot J, Verzijl N, TeKoppele JM, Breedveld FC, et al. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 10949.
  • 9
    Torsteinsdottir I, Hakansson L, Hallgren R, Gudbjornsson B, Arvidson NG, Venge P. Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 124954.
  • 10
    Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999; 17: 67682.
  • 11
    Washburn MP, Wolters D, Yates JR III. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19: 2427.
  • 12
    Wu SL, Amato H, Biringer R, Choudhary G, Shieh P, Hancock WS. Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system. J Proteome Res 2002; 1: 45965.
  • 13
    Pang JX, Ginanni N, Dongre AR, Hefta SA, Opitek GJ. Biomarker discovery in urine by proteomics. J Proteome Res 2002; 1: 1619.
  • 14
    Spahr CS, Davis MT, McGinley MD, Robinson JH, Bures EJ, Beierle J, et al. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 2001; 1: 93107.
  • 15
    Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1: 94755.
  • 16
    Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096103.
  • 17
    Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999; 17: 9949.
  • 18
    Bondarenko PV, Chelius D, Shaler TA. Identification and relative quantitation of protein mixtures by enzymatic digestion followed by capillary reversed-phase liquid chromatography-tandem mass spectrometry. Anal Chem 2002; 74: 47419.
  • 19
    Chelius D, Bondarenko PV. Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J Proteome Res 2002; 1: 31723.
  • 20
    Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004; 4: 117586.
  • 21
    Ohya T, Kaneko Y. Novel hyaluronidase from streptomyces. Biochim Biophys Acta 1970; 198: 6079.
  • 22
    Weinberger A, Simkin PA. Plasma proteins in synovial fluids of normal human joints. Semin Arthritis Rheum 1989; 19: 6676.
  • 23
    Pruzanski W, Russell ML, Gordon DA, Ogryzlo MA. Serum and synovial fluid proteins in rheumatoid arthritis and degenerative joint diseases. Am J Med Sci 1973; 265: 48390.
  • 24
    Moore RE, Young MK, Lee TD. Qscore: an algorithm for evaluating SEQUEST database search results. J Am Soc Mass Spectrom 2002; 13: 37886.
  • 25
    Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al, and The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet 2000; 25: 259.
  • 26
    Pruitt KD, Maglott DR. RefSeq and LocusLink: NCBI gene-centered resources. Nucleic Acids Res 2001; 29: 13740.
  • 27
    Larsen A. A radiological method for grading the severity of rheumatoid arthritis. Scand J Rheumatol 1975; 4: 22533.
  • 28
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 29
    Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 63768.
  • 30
    Roth J, Vogl T, Sorg C, Sunderkotter C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 2003; 24: 1558.
  • 31
    Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21: 13440.
  • 32
    Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, Zwadlo G, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987; 330: 802.
  • 33
    Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 62837.
  • 34
    Uchida T, Fukawa A, Uchida M, Fujita K, Saito K. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002; 1: 4959.
  • 35
    Sinz A, Bantscheff M, Mikkat S, Ringel B, Drynda S, Kekow J, et al. Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 2002; 23: 344556.
  • 36
    Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003; 48: 26226.
  • 37
    Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, Gunzer M, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 2003; 23: 103443.
  • 38
    Yang Z, Tao T, Raftery MJ, Youssef P, di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001; 69: 98694.
  • 39
    Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889901.
  • 40
    Petrow PK, Hummel KM, Schedel J, Franz JK, Klein CL, Muller-Ladner U, et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 2000; 43: 1597605.
  • 41
    Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 17315.
  • 42
    Harigai M, Hara M, Takahashi N, Kitani A, Hirose T, Suzuki K, et al. Presence of autoantibodies to peptidyl-prolyl cis-trans isomerase (cyclosporin A-binding protein) in systemic lupus erythematosus. Clin Immunol Immunopathol 1992; 63: 5865.
  • 43
    De Ceuninck F, Allain F, Caliez A, Spik G, Vanhoutte PM. High binding capacity of cyclophilin B to chondrocyte heparan sulfate proteoglycans and its release from the cell surface by matrix metalloproteinases: possible role as a proinflammatory mediator in arthritis. Arthritis Rheum 2003; 48: 2197206.
  • 44
    Mangold U, Dax CI, Saar K, Schwab W, Kirschbaum B, Mullner S. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem 1999; 266: 118491.
  • 45
    Yu S, Nakashima N, Xu BH, Matsuda T, Izumihara A, Sunahara N, et al. Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: in the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatol Int 1998; 17: 23743.
  • 46
    Keyszer G, Redlich A, Haupl T, Zacher J, Sparmann M, Ungethum U, et al. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase–polymerase chain reaction and immunohistochemistry. Arthritis Rheum 1998; 41: 137887.
  • 47
    Hassan MQ, Hadi RA, Al-Rawi ZS, Padron VA, Stohs SJ. The glutathione defense system in the pathogenesis of rheumatoid arthritis. J Appl Toxicol 2001; 21: 6973.
  • 48
    Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 1999; 11: 54554.
  • 49
    Davis AR, Clements MK, Bunger PL, Siemsen DW, Quinn MT. Cloning and characterization of bovine low molecular weight GTPases (Rac1 and Rac2) and rho GDP-dissociation inhibitor 2 (D4-GDI). Vet Immunol Immunopathol 2000; 74: 285301.
  • 50
    Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H. Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 2000; 274: 8792.